Project 2

项目2

基本信息

  • 批准号:
    8102547
  • 负责人:
  • 金额:
    $ 33.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-05-16 至 2015-02-28
  • 项目状态:
    已结题

项目摘要

Human papillomavirus (HPV) infection is the most common viral sexually transmitted infection (STI), and infection with high-risk types of HPV has been implicated in the majority of anogenital malignancies. Worldwide, HPV-related cervical cancer is the second most common cause of malignancy in women. Over the past 40 years in the United States, cervical cancer incidence rates have been dramatically reduced, which is believed to be the result of Pap smear screening. Incidence rates are distinctly increased in minority, underserved populations. In the United States, African American women have 30% higher incidence of cervical cancer and a 2-fold increased risk of mortality as compared to Caucasian women. These findings are more striking in Louisiana, where African American women have almost a 50% increase in incidence and a 3-fold increase in mortality over their Caucasian counterparts. Even in the African-American population, where HPV infection rates are high, relatively few women progress to cervical abnormalities. This fact indicates that HPV infection is necessary but not sufficient for the development of cervical cancer. Thus, other cofactors must augment the oncogenic potential of HPV. The known oncogenic virus, Epstein-Barr virus (EBV), is shed from the cervix, making this a prime co-factor candidate for HPV-related cervical dysplasia. Preliminary data strongly suggest that EBV may be a co-factor to HPV in the pathogenesis of cervical dysplasia, irrespective of HIV status. It is hypothesized that HIV-negative women who shed both EBV and high-risk HPV from their cervix are at greater risk for cervical dysplasia than women who shed only high-risk HPV. From this hypothesis, it is predicted that (1) the rate of cervical dysplasia will be increased in those women co-shedding both EBV and HPV; (2) EBV and HPV cervical shedding will be detected prior to the development of cervical dysplasia; (3) EBV and HPV will be located in the same cervical epithelial cells or in close proximity; (4) analysis of co-infected cervical tissue will demonstrate loss of cell cycle control pathways and inhibition of apoptosis pathways; and (5) prophylactic HPV vaccination will prevent these events.
人乳头瘤病毒(HPV)感染是最常见的病毒性性传播感染(STI),高危型HPV感染与大多数肛门生殖器恶性肿瘤有关。在世界范围内,hpv相关的子宫颈癌是女性恶性肿瘤的第二大常见原因。在过去的40年里,在美国,宫颈癌的发病率已经大大降低,这被认为是子宫颈抹片检查的结果。发病率明显增加

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BETTY P. DENNIS其他文献

BETTY P. DENNIS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BETTY P. DENNIS', 18)}}的其他基金

Project 3
项目3
  • 批准号:
    8434771
  • 财政年份:
    2013
  • 资助金额:
    $ 33.74万
  • 项目类别:
Project 2
项目2
  • 批准号:
    8434770
  • 财政年份:
    2013
  • 资助金额:
    $ 33.74万
  • 项目类别:
Impact of Man-made Disasters on the Underserved: Lesson Learned from BP Oil Spill
人为灾难对服务不足的人群的影响:英国石油公司漏油事件的教训
  • 批准号:
    8129967
  • 财政年份:
    2011
  • 资助金额:
    $ 33.74万
  • 项目类别:
Project 1
项目1
  • 批准号:
    8102545
  • 财政年份:
    2010
  • 资助金额:
    $ 33.74万
  • 项目类别:
Community Core
社区核心
  • 批准号:
    8102543
  • 财政年份:
    2010
  • 资助金额:
    $ 33.74万
  • 项目类别:
Training Core
培训核心
  • 批准号:
    8102541
  • 财政年份:
    2010
  • 资助金额:
    $ 33.74万
  • 项目类别:
Dillard-LSUHSC Minority Health and Health Disparities Research Center
迪拉德-路易斯安那州立大学HSC 少数族裔健康与健康差异研究中心
  • 批准号:
    7880307
  • 财政年份:
    2010
  • 资助金额:
    $ 33.74万
  • 项目类别:
ADMIN CORE
管理核心
  • 批准号:
    8102538
  • 财政年份:
    2010
  • 资助金额:
    $ 33.74万
  • 项目类别:
Research Core
研究核心
  • 批准号:
    8102540
  • 财政年份:
    2010
  • 资助金额:
    $ 33.74万
  • 项目类别:
Project 3
项目3
  • 批准号:
    8102550
  • 财政年份:
    2010
  • 资助金额:
    $ 33.74万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 33.74万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 33.74万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 33.74万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.74万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 33.74万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 33.74万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 33.74万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 33.74万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 33.74万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 33.74万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了